News
RVNC
21.76
+0.23%
0.05
BRIEF-Nanostics Announces New Member Of Board Of Directors
Reuters · 11/17 13:06
Barclays Maintains Overweight on Revance Therapeutics, Raises Price Target to $37
Benzinga · 11/16 12:03
--Barclays Adjusts Price Target on Revance Therapeutics to $37 From $35, Maintains Overweight Rating
--Barclays Adjusts Price Target on Revance Therapeutics to $37 From $35, Maintains Overweight Rating
MT Newswires · 11/16 09:53
What 8 Analyst Ratings Have To Say About Revance Therapeutics
Benzinga · 11/09 14:36
Morgan Stanley Maintains Equal-Weight on Revance Therapeutics, Lowers Price Target to $25
Benzinga · 11/09 13:38
Revance to Participate in the Stifel 2022 Healthcare Conference
NASHVILLE, Tenn., November 09, 2022--Revance to Participate in the Stifel 2022 Healthcare Conference
Business Wire · 11/09 13:00
--Morgan Stanley Adjusts Price Target on Revance Therapeutics to $25 From $27, Maintains Equal-Weight Rating
--Morgan Stanley Adjusts Price Target on Revance Therapeutics to $25 From $27, Maintains Equal-Weight Rating
MT Newswires · 11/09 09:47
Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Tops Revenue Estimates
Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -37.65% and 0.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/08 23:05
Revance Therapeutics GAAP EPS of -$1.17 misses by $0.23, revenue of $29M beats by $0.76M
Seekingalpha · 11/08 21:34
BRIEF-Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update
Reuters · 11/08 21:31
Revance Therapeutics Q3 EPS $(1.17) Misses $(0.89) Estimate, Sales $29.02M Beat $27.94M Estimate
Benzinga · 11/08 21:14
-- Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q3 Revenue $29M, vs. Street Est of $28.2M
-- Earnings Flash (RVNC) REVANCE THERAPEUTICS Posts Q3 Revenue $29M, vs. Street Est of $28.2M
MT Newswires · 11/08 16:33
Revance Therapeutics's Earnings: A Preview
Benzinga · 11/07 17:22
Revance Therapeutics Says Precise Frown Line Injection Technique Can Lead to Improved Results
Revance Therapeutics Says Precise Frown Line Injection Technique Can Lead to Improved Results
MT Newswires · 11/04 12:21
Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment
NASHVILLE, Tenn., November 04, 2022--Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment
Business Wire · 11/04 12:00
Here’s What Makes Revance Therapeutics (RVNC) an Attractive Investment
Baron Funds, an investment management company, released its “Baron Discovery Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. Compared to the Russell 2000 Growth Index benchmark, which was slightly positive, the fund (in...
Insider Monkey · 11/01 17:01
Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: Should You Buy?
Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 11/01 14:01
Revance Therapeutics, Inc. (NASDAQ:RVNC) insiders are undoubtedly delighted they bought last year with gains to date at US$736k
Insiders who purchased Revance Therapeutics, Inc. ( NASDAQ:RVNC ) shares in the past 12 months are unlikely to be...
Simply Wall St. · 10/24 16:02
Revance Therapeutics submits sBLA for Daxxify for cervical dystonia
Seekingalpha · 10/20 15:19
Revance Submits Supplemental Biologics License Application For DAXXIFY For Injection For The Treatment Of Cervical Dystonia
Benzinga · 10/20 12:13
More
Webull provides a variety of real-time RVNC stock news. You can receive the latest news about Revance Therapeu through multiple platforms. This information may help you make smarter investment decisions.
About RVNC
Revance Therapeutics, Inc. is a commercial stage biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and OPUL. The RHA Collection of dermal fillers is a dermal filler for the correction of dynamic facial wrinkles and folds. OPUL’s product offering includes the point-of-sale platform, software and hardware terminal.